Logo image of AMPLI.PA

AMPLITUDE SURGICAL SAS (AMPLI.PA) Stock Fundamental Analysis

Europe - EPA:AMPLI - FR0012789667 - Common Stock

6.2 EUR
0 (0%)
Last: 9/25/2025, 7:00:00 PM
Fundamental Rating

2

AMPLI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 58 industry peers in the Health Care Equipment & Supplies industry. AMPLI has a medium profitability rating, but doesn't score so well on its financial health evaluation. AMPLI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year AMPLI was profitable.
In the past year AMPLI had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: AMPLI reported negative net income in multiple years.
Each year in the past 5 years AMPLI had a positive operating cash flow.
AMPLI.PA Yearly Net Income VS EBIT VS OCF VS FCFAMPLI.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

1.2 Ratios

AMPLI's Return On Assets of 0.39% is on the low side compared to the rest of the industry. AMPLI is outperformed by 62.07% of its industry peers.
AMPLI has a worse Return On Equity (1.15%) than 62.07% of its industry peers.
AMPLI has a worse Return On Invested Capital (3.48%) than 62.07% of its industry peers.
The Average Return On Invested Capital over the past 3 years for AMPLI is significantly below the industry average of 8.65%.
The last Return On Invested Capital (3.48%) for AMPLI is above the 3 year average (2.94%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 0.39%
ROE 1.15%
ROIC 3.48%
ROA(3y)4.54%
ROA(5y)0.64%
ROE(3y)11.48%
ROE(5y)-1.81%
ROIC(3y)2.94%
ROIC(5y)N/A
AMPLI.PA Yearly ROA, ROE, ROICAMPLI.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

AMPLI has a Profit Margin (1.00%) which is comparable to the rest of the industry.
AMPLI has a Operating Margin of 10.22%. This is comparable to the rest of the industry: AMPLI outperforms 51.72% of its industry peers.
The Gross Margin of AMPLI (79.74%) is better than 93.10% of its industry peers.
AMPLI's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 10.22%
PM (TTM) 1%
GM 79.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.67%
GM growth 5Y9.09%
AMPLI.PA Yearly Profit, Operating, Gross MarginsAMPLI.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

1

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so AMPLI is destroying value.
Compared to 1 year ago, AMPLI has about the same amount of shares outstanding.
The number of shares outstanding for AMPLI has been increased compared to 5 years ago.
AMPLI has a worse debt/assets ratio than last year.
AMPLI.PA Yearly Shares OutstandingAMPLI.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AMPLI.PA Yearly Total Debt VS Total AssetsAMPLI.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of 1.41, we must say that AMPLI is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 1.41, AMPLI is not doing good in the industry: 60.34% of the companies in the same industry are doing better.
AMPLI has a Debt/Equity ratio of 1.11. This is a high value indicating a heavy dependency on external financing.
AMPLI's Debt to Equity ratio of 1.11 is on the low side compared to the rest of the industry. AMPLI is outperformed by 82.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF N/A
Altman-Z 1.41
ROIC/WACC0.5
WACC7.01%
AMPLI.PA Yearly LT Debt VS Equity VS FCFAMPLI.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 1.91 indicates that AMPLI should not have too much problems paying its short term obligations.
AMPLI has a Current ratio of 1.91. This is comparable to the rest of the industry: AMPLI outperforms 58.62% of its industry peers.
A Quick Ratio of 0.94 indicates that AMPLI may have some problems paying its short term obligations.
AMPLI has a Quick ratio of 0.94. This is in the lower half of the industry: AMPLI underperforms 62.07% of its industry peers.
Industry RankSector Rank
Current Ratio 1.91
Quick Ratio 0.94
AMPLI.PA Yearly Current Assets VS Current LiabilitesAMPLI.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for AMPLI have decreased strongly by -97.47% in the last year.
The Revenue has been growing slightly by 4.25% in the past year.
The Revenue has been growing slightly by 0.67% on average over the past years.
EPS 1Y (TTM)-97.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-245.95%
Revenue 1Y (TTM)4.25%
Revenue growth 3Y8.63%
Revenue growth 5Y0.67%
Sales Q2Q%4.99%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AMPLI.PA Yearly Revenue VS EstimatesAMPLI.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
AMPLI.PA Yearly EPS VS EstimatesAMPLI.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 0 -0.05 -0.1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 310.00, AMPLI can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of AMPLI is on the same level as its industry peers.
When comparing the Price/Earnings ratio of AMPLI to the average of the S&P500 Index (27.06), we can say AMPLI is valued expensively.
Industry RankSector Rank
PE 310
Fwd PE N/A
AMPLI.PA Price Earnings VS Forward Price EarningsAMPLI.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

The rest of the industry has a similar Enterprise Value to EBITDA ratio as AMPLI.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 15.95
AMPLI.PA Per share dataAMPLI.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AMPLI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMPLITUDE SURGICAL SAS

EPA:AMPLI (9/25/2025, 7:00:00 PM)

6.2

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-17 2025-04-17
Earnings (Next)10-22 2025-10-22
Inst Owners0.11%
Inst Owner ChangeN/A
Ins Owners0.26%
Ins Owner ChangeN/A
Market Cap297.72M
Analysts40
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 310
Fwd PE N/A
P/S 2.74
P/FCF N/A
P/OCF 50.17
P/B 3.14
P/tB N/A
EV/EBITDA 15.95
EPS(TTM)0.02
EY0.32%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)0.12
OCFY1.99%
SpS2.26
BVpS1.97
TBVpS-0.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.39%
ROE 1.15%
ROCE 4.78%
ROIC 3.48%
ROICexc 3.8%
ROICexgc 10.4%
OM 10.22%
PM (TTM) 1%
GM 79.74%
FCFM N/A
ROA(3y)4.54%
ROA(5y)0.64%
ROE(3y)11.48%
ROE(5y)-1.81%
ROIC(3y)2.94%
ROIC(5y)N/A
ROICexc(3y)3.37%
ROICexc(5y)N/A
ROICexgc(3y)9.91%
ROICexgc(5y)N/A
ROCE(3y)4.01%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.67%
GM growth 5Y9.09%
F-Score7
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF N/A
Debt/EBITDA 4.25
Cap/Depr 137.68%
Cap/Sales 17.25%
Interest Coverage 250
Cash Conversion 24.04%
Profit Quality N/A
Current Ratio 1.91
Quick Ratio 0.94
Altman-Z 1.41
F-Score7
WACC7.01%
ROIC/WACC0.5
Cap/Depr(3y)129.83%
Cap/Depr(5y)100.73%
Cap/Sales(3y)17.03%
Cap/Sales(5y)14.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-97.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-245.95%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.25%
Revenue growth 3Y8.63%
Revenue growth 5Y0.67%
Sales Q2Q%4.99%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.6%
OCF growth 3Y19.93%
OCF growth 5Y-13.28%